Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Affimed NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AFMD
Nasdaq
8731
https://www.affimed.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Affimed NV
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
- Jun 10th, 2022 2:31 pm
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
- Jun 1st, 2022 11:55 am
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
- Jun 1st, 2022 10:30 am
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
- May 26th, 2022 9:05 pm
Affimed to Present at the 2022 Jefferies Healthcare Conference
- May 26th, 2022 10:30 am
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- May 25th, 2022 7:00 pm
Affimed Announces Annual General Meeting of Shareholders
- May 24th, 2022 10:30 am
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
- May 24th, 2022 10:30 am
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
- May 16th, 2022 12:00 pm
What Percentage Of Affimed N.V. (NASDAQ:AFMD) Shares Do Insiders Own?
- May 14th, 2022 12:06 pm
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
- May 12th, 2022 2:31 pm
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
- May 6th, 2022 8:02 pm
CORRECTING and REPLACING -- Affimed N.V.
- Apr 27th, 2022 9:21 pm
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for Cancer Research (ASCO)
- Apr 27th, 2022 8:05 pm
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Apr 18th, 2022 3:28 pm
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
- Apr 13th, 2022 2:02 am
Affimed Announces Proposed Public Offering of Common Shares
- Apr 12th, 2022 8:03 pm
Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings
- Apr 11th, 2022 7:59 pm
Why Affimed Stock Is Heating Up Today
- Apr 11th, 2022 4:22 pm
SVB Leerink: Affimed's data for experimental Hodgkin's therapy is 'validating'
- Apr 11th, 2022 12:09 pm
Scroll